KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(V and its ETHEX generic/non-branded ...),Health

drug subsidiary by the branded pharmaceutical maker Solvay

Pharmaceuticals, Inc. pertaining to certain pancreatic enzyme products;

and

-- Received in July 2007 FDA approval for the marketing of Evamist(TM) by

VIVUS, Inc. for which KV acquired exclusive U.S. marketing rights from

VIVUS. Evamist(TM) is expected to be launched prior to fiscal 2008

year-end.

Financial Condition:

The financial condition of the Company remains strong. The Company held cash and marketable securities of $240.4 million at fiscal 2007 year-end. The Company is actively evaluating and pursuing acquisition and other commercial opportunities that are consistent with its strategic goals. Subsequent to fiscal year-end the Company has made sizable additional investments in new products, including by acquisition and internal development.

Highlights are as follows:

-- Debt-to-equity ratio of 0.66-to-1 as of March 31, 2007

-- Working capital of $372.3 million as of March 31, 2007

-- 20.7% increase in net revenues

-- 21.6% increase in gross profit

-- 408.8% increase in net income

-- 356.5% increase in diluted earnings per Class A Common share

Fiscal 2008 Potential Growth Factors:

KV anticipates its 13th consecutive year of record revenues in fiscal 2008. Factors expected to contribute to continued performance include:
-- Continued revenue growth and market share gain for KV's Clindesse(R)

branded prescription, one-dose intra-vaginal treatment for BV;

-- Continued revenue growth and market share gain for KV's prescription

prenatal product lines, in particular, PrimaCare(R) ONE;

-- Significant revenue contribution from the marketing of the 100 mg and

200 mg strengths of metoprolol succinate during the 180-day exclusivity

period granted by the FDA;

-- Continued revenue g
'/>"/>